Dicerna Pharmaceuticals NASDAQ:DRNA is reporting this earnings, what to expect.
Dicerna Pharmaceuticals NASDAQ:DRNA headquartered in Watertown, Massachusetts, United States is reporting their earnings on 05/14/2018 before the bell. Street forecast for the quarter ending March 2018 is $-0.41.
According to stock market daily analyst this is Lower then same time previous year. Dicerna Pharmaceuticals reported EPS for the same quarter last year was $-0.68.
Overview of Dicerna Pharmaceuticals NASDAQ:DRNA
Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes.
Dicerna proprietary, next-generation technology, known as RNA interference or RNAi, uses the body’s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health.
Dicerna is advancing a growing pipeline of product candidates, with our DCR-PHXC lead program in clinical development for the treatment of a progressive and debilitating rare disease called primary hyperoxaluria, or PH. We filed a clinical trial application in the UK in the fourth quarter of 2017 and initiated human dosing in a Phase 1 clinical trial of DCR-PHXC in December of 2017. The Company plans to dose the first patient in second quarter of 2018 and expects to have clinical proof-of-concept (“POC”) data in the second half of 2018. We have submitted CTAs in Germany, France and the Netherlands. Additionally, we expect to initiate a multi-dose Phase 2/3 study in the first quarter of 2019, pending positive POC data and regulatory approvals.
|% Change from 52 Week Low|
|% Change from 52 Week High|